{
  "docId": "019de076-567f-77cd-b2fe-46fe5b90ebce",
  "docSlug": "f071473f2318bf29da28de95df17ba43",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Focuses on patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-567f-77cd-b2fe-46fe5b90ebce/14",
  "deckHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce",
  "deckJsonHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce.json",
  "deckAnchorHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cce6fb9-a2e2-4980-be32-5a496e7c18f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "list",
      "text": "All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1af4aee2-5776-4bc2-9670-fce73c81e6c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "list",
      "text": "13 patients with no other treatment options are currently receiving or have completed treatment with MAT2203. Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nationwide Children’s Hospital, Vanderbilt University Medical Center.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b57203c-f6b6-4d94-81d5-0f133173d97b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "list",
      "text": "Renal toxicity reversed and renal function returned to baseline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3297b8d5-0a94-4dfb-8d45-33f6c84ec30d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "Following oral MAT2203 initiation, patients were discharged to continue treatment at home.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bfd7425-edd9-4181-b621-43c73673a164",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Patients were switched to treatment with IV Amphotericin B with clinical response but unable to tolerate treatment due renal toxicity. All patients hospitalized to monitor/manage renal safety and most received IV electrolyte supplementation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa30da3e-bfe2-4be5-af0f-22d11da0e39b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.48
      },
      "kind": "list",
      "text": "Patients were not responding/resistant to, or unable to receive, azole therapy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b128da05-932a-4c6f-bcde-23f4c774c7b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "MAT2203 Expanded Access/Compassionate Use Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bece844-edc4-4f64-8451-4eb0ab2734a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e8350fd-f8e5-46e3-b847-1504c590f092",
      "evidence": "The Growing Threat of Invasive Fungal Infections (IFIs) and High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "position": 0,
      "objective": "Highlight the high unmet medical need in treatment of invasive aspergillosis (IA)",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}